养生
多西紫杉醇
表阿霉素
肿瘤科
医学
内科学
吉西他滨
诱导化疗
鼻咽癌
顺铂
氟尿嘧啶
化疗
放射治疗
环磷酰胺
作者
Ting Liu,Shuang Dai,Hao Zhang,Xi Zhong,Zhenyu Ding,Xuelei Ma
出处
期刊:Head & neck
[Wiley]
日期:2021-12-04
卷期号:44 (2): 518-529
被引量:6
摘要
Abstract The determination of the optimal induction chemotherapy (IC) regimen for patients with locally advanced nasopharyngeal carcinoma (NPC) remains controversial. Eligible trials included in this Bayesian network meta‐analysis were judged by synthetically evaluating survival and safety outcomes. The analysis revealed that the combined IC regimen of gemcitabine plus cisplatin (GP) gained not only the most favorable overall survival (OS) benefit but also longer distant metastasis‐free survival and manageable adverse events (AEs). Additionally, combination IC regimen of mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin had insufficient significant efficacy on complete response. Docetaxel combined with cisplatin and fluorouracil induction regimen provided the first exact probability of efficacy in term of local recurrence‐free survival, ranking second in OS, but accompanied by the highest rates of grade 3 or above AEs. GP regimen appears to be currently the best choice of IC regimen for combined benefit of patients with locally advanced NPC.
科研通智能强力驱动
Strongly Powered by AbleSci AI